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Introduction: Malaria is the most relevant parasitic disease worldwide, and still accounts for 1 million deaths each year.
Since current antimalarial drugs are unable to prevent death in severe cases, new therapeutic strategies have been
developed. Mesenchymal stromal cells (MSC) confer host resistance against malaria; however, thus far, no study has
evaluated the therapeutic effects of MSC therapy on brain and distal organ damage in experimental cerebral malaria.
Methods: Forty C57BL/6 mice were injected intraperitoneally with 5 × 106 Plasmodium berghei-infected erythrocytes
or saline. After 24 h, mice received saline or bone marrow (BM)-derived MSC (1x105) intravenously and were housed
individually in metabolic cages. After 4 days, lung and kidney morphofunction; cerebrum, spleen, and liver histology;
and markers associated with inflammation, fibrogenesis, and epithelial and endothelial cell damage in lung tissue were
analyzed.
Results: In P. berghei-infected mice, BM-MSCs: 1) reduced parasitemia and mortality; 2) increased phagocytic
neutrophil content in brain, even though BM-MSCs did not affect the inflammatory process; 3) decreased malaria
pigment detection in spleen, liver, and kidney; 4) reduced hepatocyte derangement, with an increased number
of Kupffer cells; 5) decreased kidney damage, without effecting significant changes in serum creatinine levels or
urinary flow; and 6) reduced neutrophil infiltration, interstitial edema, number of myofibroblasts within interstitial
tissue, and collagen deposition in lungs, resulting in decreased lung static elastance. These morphological and
functional changes were not associated with changes in levels of tumor necrosis factor-α, keratinocyte-derived
chemokine (KC, a mouse analog of interleukin-8), or interferon-γ, which remained increased and similar to those
of P. berghei animals treated with saline. BM-MSCs increased hepatocyte growth factor but decreased VEGF in the
P. berghei group.
Conclusions: BM-MSC treatment increased survival and reduced parasitemia and malaria pigment accumulation
in spleen, liver, kidney, and lung, but not in brain. The two main organs associated with worse prognosis in
malaria, lung and kidney, sustained less histological damage after BM-MSC therapy, with a more pronounced
improvement in lung function.* Correspondence: prmrocco@biof.ufrj.br
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Malaria is the most relevant parasitic disease worldwide.
Despite efforts toward its eradication, malaria still
accounts for 1 million deaths each year [1]. Cerebral
malaria is characterized by multiple organ dysfunction
triggered by circulating parasitized red blood cells
(RBCs). Besides the brain, highly vascularized organs
such as the lungs and kidneys are especially affected
during cerebral malaria. In fact, of patients with cerebral
malaria 20–30 % develop acute respiratory distress syn-
drome (ARDS) [2] and 40–50 % develop acute renal fail-
ure [3]. Disruption of the blood–brain barrier (BBB),
sequestration of parasitized RBCs in the brain, lung, and
kidneys, and a systemic inflammatory response, includ-
ing production of cytokines and activation of inflamma-
tory cells, have been consistently observed in both
human and nonprimate models of cerebral malaria [4].
Recent studies report that current antimalarial drugs are
insufficient to prevent death in severe cases of malaria;
thus, adjunctive therapies aiming to modulate the sys-
temic inflammatory response triggered by malaria have
been proposed [5].
The beneficial effects of cell therapy have been demon-
strated not only in infectious diseases [6–8] but also in
parasitic diseases [9–12]. Mesenchymal stromal cells
(MSCs) attenuated liver injury by diminishing the pro-
duction of proinflammatory mediators in schistosomiasis
[10] and decreased liver fibrosis induced by Trypano-
soma cruzi infection [11]. Using a model of noncerebral
malaria, Belyaev et al. [12] reported that treatment of
mice infected with Plasmodium chabaudi (a Plasmo-
dium species that does not induce cerebral malaria) with
lymphoid-primed multipotent progenitor cells decreased
parasitemia, probably by inducing a phagocytic active
cell population. Accordingly, experimental cerebral mal-
aria (ECM)-resistant mice treated with cells expressing
stem cell antigen-1 exhibited decreased parasitemia and
an increased survival rate when compared with non-
treated mice [13]. However, no study has thus far evalu-
ated the effects of mesenchymal stem cell therapy on
brain, spleen, liver, kidney, and lung damage in ECM. In
the present study, we hypothesized that bone marrow-
derived mesenchymal stromal cells (BM-MSCs) might
reduce mortality in ECM by acting not only in the brain
but also in other organs.
Methods
This work was carried out in strict accordance with the
recommendations of the US National Research Council
Guide for the Care and Use of Laboratory Animals. The
study protocol was approved by the Committee on Ethical
Use of Laboratory Animals of the Oswaldo Cruz Founda-
tion (permit number LW52/12) and by the Research Eth-
ics Committee of the Federal University of Rio de JaneiroHealth Sciences Center (CEUA-CCS-019). All animals
received humane care in compliance with the “Principles
of Laboratory Animal Care” formulated by the National
Society for Medical Research.
Extraction, isolation, and characterization of BM-MSCs
Bone marrow cells were obtained from femurs and tib-
ias. After isolation, 1 × 107 bone marrow-derived cells
were cultured (37 °C, 5 % CO2) in T25 culture flasks
(TPP, Schaffhausen, Switzerland) with Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA, USA)
containing 15 mM HEPES (Sigma, St. Louis, MO, USA),
15 % inactivated fetal bovine serum (FBS; Invitrogen), 100
units/ml penicillin, and 100 mg/ml streptomycin antibiotic
solution (Gibco, Carlsbad, MO, USA) [14]. On day 3 of
culture, the medium was changed and nonadherent cells
were removed. Adherent cells reaching 80 % confluence
were passaged with 0.05 % trypsin–Ethylenediaminetetra-
acetic acid solution (Gibco) and then maintained in
DMEM with 10 % FBS (complete medium). At the third
passage, approximately 1 × 106 cells were characterized as
BM-MSCs according to the International Society of Cellu-
lar Therapy Consensus, i.e., adherent to plastic under
standard conditions, expressing some surface markers
(CD73, CD90, and CD105) and lacking expression of
others (CD34, CD45, CD11b, and CD19), and demonstrat-
ing capacity to differentiate into mesenchymal lineages
under in vitro conditions [15]. Flow cytometry was per-
formed with antibodies against CD45 (leukocytes), CD34
(hematopoietic precursors), CD29 and CD45 (nonhemato-
poietic precursors), and Sca-1 (stem/progenitor cells) (BD
Biosciences, San Jose, CA, USA). The absence of CD34
and CD45 and the presence of CD29 and Sca-1 were used
to identify MSCs [16]. To measure the small-angle for-
ward scatter (FSC) intensity (~0–5°) and the limited-angle
side scatter (SSC) intensity (~85–95°), a photodiode and a
photomultiplier tube were used respectively. Additionally,
the potential of MSCs to differentiate into mesenchymal
lineages including osteoblasts and chondroblasts under
in vitro conditions was evaluated. Osteogenic differenti-
ation was induced by culturing MSCs for up to 3 weeks in
DMEM 10 % FBS and 15 mM HEPES (Sigma), supple-
mented with 10–8 M/l dexamethasone (Sigma), 5 μg/ml
ascorbic acid 2-phosphate (Sigma), and 10 mM/l β-
glycerolphosphate (Sigma). To observe calcium depos-
ition, cultures were stained with Alizarin Red S (Nuclear,
São Paulo, SP, Brazil). To induce chondrogenic differenti-
ation, MSCs were cultured in DMEM supplemented with
10 ng/ml transforming growth factor (TGF)-β1 (Sigma),
50 nM ascorbic acid 2-phosphate (Sigma), and 6.25 mg/
ml insulin for 3 weeks. To confirm differentiation, cells
were fixed with 4 % paraformaldehyde in phosphate-
buffered saline (PBS) for 1 hour at room temperature and
stained with Alcian Blue pH 2.5.
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A total of 92 C57BL/6 male mice (6–7 weeks old) were
used. In 72 mice, the lung mechanics, renal function,
and brain, spleen, liver, kidney, and lung histology were
analyzed, and enzyme-linked immunosorbent assay
(ELISA) was performed in lung tissue. All experimental
conditions were repeated in triplicate (n = 6/group). The
remaining 20 mice were used to evaluate the survival
rate. Mice were provided by the Oswaldo Cruz Founda-
tion breeding unit (Rio de Janeiro, RJ, Brazil) and kept in
cages in a room at the Farmanguinhos experimental
facility, with free access to food and fresh water,
temperature ranging from 22 to 24 °C, and a standard
12-hour light/dark cycle, until experimental use. All ani-
mals were randomly assigned to two groups: uninfected
or Plasmodium berghei-infected. P. berghei ANKA
GFPcon 259 cl2 was kindly provided by Dr. L. Carvalho
(Fiocruz, Rio de Janeiro, RJ, Brazil) and is a donation
from the Malaria Research and Reference Reagent
Resource Center—MR4 (Manassas, VA, USA; deposited
by C.J. Janse and A.P. Waters; MR4 number: MRA-865).
Mice were infected by injection intraperitoneally (i.p.) of
P. berghei-infected RBCs withdrawn from a previously
infected mouse (5 × 106 infected RBCs diluted in 200 μl
sterile saline solution). Uninfected mice received saline
alone (200 μl, i.p.). Twenty-four hours after infection,
the uninfected and P. berghei groups were further ran-
domized into subgroups to receive saline (0.05 ml) or
BM-MSC (1 × 105 in 0.05 ml saline) intravenously into
the internal jugular vein. Five days after infection, sur-
viving mice were euthanized by injection i.p. of a mix-
ture of ketamine (100 mg/kg) and xylazine (10 mg/kg)
followed by pentobarbital sodium (150 mg/kg). Five days
after infection, a thick blood smear was performed for
determination of parasitemia by rapid panoptic staining
(Laborclin, Paraná, Brazil).
To calculate the survival rate, lethality in the treated
(n = 10) and untreated (n = 10) subgroups of P. berghei-
infected mice was recorded daily until day 20 post
infection.
Immunofluorescent staining and flow cytometric analysis
Splenocytes from C57BL/6 mice were isolated by
Histopaque-1077 (Sigma, St. Loius, MO, USA). One hour
after treatment, cells were washed and then incubated in
PBS plus 10 % FBS and 0.1 % sodium azide (PBS-S;
Sigma-Aldrich) and blocked with FcγIIR monoclonal anti-
bodies (mAbs; 1:100, CD16/CD32; BD Pharmingen, San
Jose, CA, USA) for 30 minutes at 4 °C. After blocking,
cells were labeled with fluorescein isothiocyanate (FITC)-
conjugated mAb anti-mouse CD11b antibodies diluted in
PBS-S and incubated for another 30 minutes at 4 °C. Cells
were then washed and resuspended in PBS/0.1 % sodium
azide for data acquisition in an Accuri flow cytometer (BDBiosciences). FSC and SSC were set to exclude dead cells,
and at least 104 lymphocytes were analyzed per sample.
Control staining to determine the positive population was
performed based on an irrelevant IgG isotype labeled with
FITC. Once determined, the gate was rigorously main-
tained for all analyses. Data analysis was performed using
FlowJo software (Tree Star, Inc., Ashland, OR, USA).
Measurement of renal and lung function
Immediately after treatment with BM-MSCs, mice were al-
located individually to metabolic cages and kept in a
temperature-controlled room under a 12-hour light/dark
cycle, with free access to food and water. After 24 hours of
adaptation, 24-hour urine samples were collected from the
different experimental groups 1 day before euthanasia,
which was performed on postinfection day 5. Urine samples
were clarified by centrifugation at 600 × g for 5 minutes and
the supernatant was separated and stored at −20 °C until
use. Urine samples were assayed colorimetrically to deter-
mine total protein levels, using specific commercially avail-
able kits (Gold Analisa kit 498 M; Gold Analisa Diagnóstica,
Belo Horizonte, MG, Brazil) in accordance with the manu-
facturer’s instructions. On postinfection day 5, the animals
were anesthetized with ketamine (80 mg/kg body weight)
and xylazine (5 mg/kg body weight), tracheotomized, para-
lyzed (vecuronium bromide, 0.005 mg/kg intravenously),
and ventilated with a constant flow ventilator (Samay VR15;
Universidad de la Republica, Montevideo, Uruguay) set to
the following parameters: rate 100 breaths/minute, tidal vol-
ume (VT) 0.2 ml, and fraction of inspired oxygen (FiO2)
0.21. The anterior chest wall was surgically removed and a
positive end-expiratory pressure of 2 cmH2O was applied.
Airflow and tracheal pressure (Ptr) were measured. Lung
mechanics were analyzed by the end-inflation occlusion
method. In an open chest preparation, Ptr reflects transpul-
monary pressure (PL). Static lung elastance (Est,L) was deter-
mined by dividing the elastic recoil pressure (Pel) by VT.
Lung mechanics parameters were measured ten times in
each animal. All data were analyzed using ANADAT soft-
ware (RHT-InfoData, Inc., Montreal, QC, Canada). All ex-
periments lasted less than 15 minutes. Blood samples were
then collected via cardiac puncture into heparinized tubes
and centrifuged at 600 × g for 5 minutes to separate plasma.
Urine and blood samples were assayed to determine the
levels of creatinine (Gold Analisa kit 427E; Gold Analisa
Diagnóstica, Belo Horizonte, MG, Brazil) and blood urea ni-
trogen (BUN; Gold Analisa kit 335; Gold Analisa Diagnós-
tica, Belo Horizonte, MG, Brazil). The glomerular filtration
rate (GFR) was derived from the creatinine clearance.
Prior to removal of the brain, liver, kidney, spleen, and
lungs, a laparotomy was performed, heparin injected
intravenously, the trachea clamped at end expiration,
and the abdominal aorta and vena cava sectioned to kill
the animals by exsanguination.
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The brain, liver, kidney, spleen, and lungs were fixed in 4 %
buffered formaldehyde, embedded in paraffin, and cut into
4-μm-thick slices, which were stained with hematoxylin
and eosin (Vetec Química Fina, Rio de Janeiro, Brazil). A
five-point, semiquantitative, severity-based scoring system
was used to assess the degree of injury as follows: 0 = nor-
mal tissue; 1 = damage to 1–25 % of total tissue examined;
2 = damage to 26–50 % of total tissue examined; 3 = dam-
age to 51–75 % of total tissue examined; and 4 = damage to
76–100 % of total tissue examined. The following
parameters were analyzed: presence of malaria pigment,
inflammation, fibrosis, and histoarchitectural damage. Lung
histology was also examined using an integrating eyepiece
with a coherent system consisting of a grid with 100 points
and 50 lines of known length coupled to a conventional
light microscope (Olympus BX51; Olympus Latin America
Inc., São Paulo, SP, Brazil). The number of mononuclear
and polymorphonuclear cells in pulmonary tissue was de-
termined by the point-counting technique [17] across ten
random, noncoincident microscopic fields [18]. These ana-
lyses were performed by an expert in lung pathology
blinded to the experimental protocol.
ELISA in lung tissue
Levels of tumor necrosis factor (TNF)-α, interferon (IFN)-
γ, chemokine (C-X-C motif) ligand (CXCL)-1, hepatocyte
growth factor (HGF), TGF-β, and vascular endothelial
growth factor (VEGF) were quantified in lung tissue.
Briefly, the lungs were excised and homogenized in cell
lysis buffer (20 mM Tris, 150 mM NaCl, 5 mM KCl, 1 %
Triton X-100, protease inhibitor cocktail (1:1000); Sigma-
Aldrich), and immediately frozen at −80 °C. The total
protein content of each tissue homogenate was evaluated
by the Bradford method, followed by determination ofFig. 1 Survival rate and parasitemia of P. berghei-infected mice. Mice were
and, 24 hours after infection, were treated with BM-MSCs. a Survival of mice in
using light microscopy. Values are expressed as means ± SD of six anima
mesenchymal stromal cell, Sal salinecytokine production by a standard sandwich ELISA, per-
formed in accordance with manufacturer instructions
(R&D Systems, Minneapolis, MN, USA). Plates were read
at 490 nm in an M5 Spectrophotometer (Molecular De-
vices, Sunnyvale, CA, USA).
Statistical analysis
Survival analysis was performed using the Kaplan–Meier
method and the log-rank (Mantel–Cox) test. Comparison
between groups was performed using two-way analysis of
variance followed by Tukey’s test. Parametric data were
expressed as mean ± standard deviation (SD), and nonpara-
metric data were expressed as median and interquartile
range. All tests were performed using PASW Statistics for
Windows, Version 18.0 (SPSS Inc., Chicago, IL, USA). Stat-
istical significance was established as p <0.05.
Results
BM-MSC treatment increased survival rate in P. berghei-
infected mice
All untreated P. berghei-infected mice succumb to infection
within 12 days. Even though BM-MSC therapy appeared to
increase the mortality rate at early time points, evaluation
of the full time course allows for the conclusion that BM-
MSC therapy increased survival as compared with non-
treatment of P. berghei-infected mice (Fig. 1a). At day 5
after infection, parasitemia was analyzed, and treatment
with BM-MSCs was found to have decreased parasitemia
levels (Fig. 1b).
Cerebral damage observed during ECM was not modulated
by BM-MSC administration
Photomicrographs of brain tissue (Fig. 2a) from uninfected
and P. berghei-infected mice treated or not with BM-MSC
were obtained on postinfection day 5. Brains collected frominfected with 5 × 106 parasitized RBCs or mock-infected with saline
fected with P. berghei. b Parasitemia was analyzed 5 days after infection
ls per group out of three experiments. BM-MSC bone marrow-derived
Fig. 2 a Photomicrographs of brain tissue stained with hematoxylin and eosin. Original magnification × 1000; bars = 100 μm. Mice were inoculated
with 5 × 106 parasitized RBCs or saline and treated with BM-MSCs. Brains were excised 5 days after infection. Normal brain cortex with neurons,
astrocytes, and oligodendrocytes (single white arrows). Treatment with BM-MSCs did not affect the brain cortex, which displays normal neurons, astrocytes,
and oligodendrocytes (black single arrows). In P. berghei-infected mice treated with saline, neurons were damaged, with an increased number of astrocytes
and oligodendrocytes (double white arrows). In P. berghei-infected mice treated with BM-MSCs, brain damage was repaired, with an increased number of
astrocytes and oligodendrocytes within neutrophils (double black arrows). b A semiquantitative, severity-based score was used to measure inflammation
and histoarchitectural damage in brains of mice infected with P. berghei or mock-infected with saline. Twenty-four hours after infection, mice were treated
with BM-MSCs. Values are expressed as median (interquartile range) of six animals in each group. *Significantly different from uninfected group (p <0.05).
BM-MSC bone marrow-derived mesenchymal stromal cell, Sal saline
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MSCs) exhibited similar histological patterns, characterized
by normal brain cortex with neurons, astrocytes, and oligo-
dendrocytes. In brains from P. berghei-infected mice we ob-
served neuron damage associated with an increased
number of astrocytes and oligodendrocytes. In brains from
BM-MSC-treated P. berghei-infected mice there was a fur-
ther increase in the number of astrocytes and oligodendro-
cytes, suggesting tissue repair. Semiquantitative analysis ofbrain damage revealed no significant differences in tissue
inflammation or degree of histoarchitectural damage be-
tween the treated and nontreated P. berghei-infected groups
(Fig. 2b). Neither malaria pigment nor fibrosis was detected
in brain tissue of animals from either of the studied groups.
BM-MSC treatment increased clearance of parasitized RBCs
Spleens from P. berghei-infected mice showed evidence of
tissue damage, with activation of lymphocytes in white
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pulp (Fig. 3b). BM-MSC administration did not affect
spleen histology in uninfected mice (Fig. 3a, b); however,
administration of BM-MSCs reduced levels of malaria pig-
ment and increased the CD11b+ cell count in spleens of P.
berghei-infected mice (Fig. 3c).
BM-MSC treatment increased the number of Kupffer cells
in liver
Administration of BM-MSCs to uninfected mice did not
alter the liver architecture (Fig. 4a). In P. berghei-infected
mice, we observed hepatocyte derangement, increased de-
position of malaria pigment, and an increased number of
Kupffer cells (Fig. 4b). After BM-MSC therapy, there was
an increase in the number of regenerated hepatocytes and
Kupffer cells (phagocytic cells) (Fig. 4a).
BM-MSC treatment mitigated the histopathological
features of P. berghei-induced kidney injury, but did not
improve renal function
Administration of BM-MSCs to uninfected mice did not
affect the normal kidney architecture (Fig. 5a, b). P. berghei
infection induced mesangial proliferation in the glomeruli
accompanied by increased deposition of malaria pigment
(Fig. 5a, b). P. berghei-infected mice treated with BM-MSCs
exhibited restoration of mesangial cell architecture and
tubular cells, as well as decreased deposition of malaria pig-
ment (Fig. 5b).
Concerning renal function, P. berghei-infected mice
exhibited a 50 % reduction in urinary flow (Fig. 6a),
while there was a threefold increase in serum creatinine
(Fig. 6b) and BUN (Fig. 6c) as compared with the unin-
fected group. The alterations in urinary flow and serum
creatinine were reflected by a sixfold decrease in creatin-
ine clearance (Fig. 6d). No changes in the BUN/serum
creatinine ratio or in urinary creatinine levels were ob-
served in the infected group (Fig. 6e and f, respectively).
BM-MSC treatment in infected mice did not change any
of these parameters. Interestingly, uninfected mice that
received BM-MSCs had increased serum creatinine and
a significant reduction in urinary creatinine. The base-
line creatinine clearance of uninfected mice was there-
fore reduced by BM-MSC treatment. The enhancement
in serum creatinine levels observed in uninfected mice
treated with BM-MSCs led to a decrease in the BUN/
serum creatinine ratio. Furthermore, we observed that
the increased urinary protein/creatinine ratio (UPCr) in-
duced by P. berghei was significantly lower after BM-
MSC treatment (Fig. 6g).
BM-MSC improved lung mechanics and reduced lung
inflammation in P. berghei-infected mice
P. berghei-infected mice also exhibited lung damage, as
characterized by structural derangements, thickening ofthe alveolar–capillary membrane, increased mononuclear
cell and fibroblast counts, and malaria pigment deposition
(Fig. 7a, b). After BM-MSC administration, reductions
were observed in the thickness of the alveolar–capillary
barrier, the number of myofibroblasts within interstitial
tissue, collagen deposition (Fig. 7a), and neutrophil counts
(Fig. 8b); however, there was an increase in the number of
mononuclear cells (Fig. 8a).
Static lung elastance (Est,L) was increased in P.
berghei-infected mice when compared with uninfected
mice (Fig. 8c). BM-MSC administration reduced Est,L in
P. berghei-infected mice.
P. berghei-infected mice exhibited increased levels of
TNF-α, IFN-γ, CXCL-1/KC, and VEGF and reduced
levels of TGF-β1 in lung tissue as compared with unin-
fected animals. No significant differences in HGF levels
were observed between the P. berghei-infected and unin-
fected groups. BM-MSC administration increased TNF-
α, TGF-β1, and HGF levels and reduced VEGF levels,
but did not modulate the production of IFN-γ or CXCL-
1/KC in P. berghei-infected mice (Fig. 9).
Discussion
In the model of ECM employed in this study, the reduc-
tion in mortality rate observed after BM-MSC therapy
was not associated with a reduction in brain damage.
Even though histological evidence of lung, liver, kidney,
and spleen injury was reduced, only lung function im-
proved after therapy. These morphological and func-
tional changes were not associated with a reduction in
proinflammatory mediators, but rather with decreased
peripheral parasitemia.
The use of BM-MSCs in diseases characterized by
brain dysfunction has been extensively described. Au-
thors have reported that BM-MSCs exert a beneficial ef-
fect in a paracrine fashion, by enhancing synaptic
transmission and ameliorating microglial signaling [19–
21]. In addition, the use of BM-MSCs as a therapeutic
approach that targets host defenses has been proposed
in bacterial diseases, including tuberculosis [22] and
parasitic diseases [10, 11]. It is interesting to note that
the parasitic conditions in which BM-MSC therapy has
been studied are characterized by involvement of specific
organs, such as the liver and heart, which reinforces the
need for studies of parasitosis that feature multiple
organ dysfunction, such as malaria. Indeed, previous
studies concerning cell therapy during malaria infection
have already been performed [12, 13, 23]. However, our
study was the first designed to evaluate the effects of
BM-MSC therapy in multiple organ dysfunction during
ECM.
Accordingly, for the present study we used a model of
ECM known to be associated with multiple organ dys-
function [24]. Mice succumb to ECM between 5 and 10
Fig. 3 (See legend on next page.)
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Fig. 3 a Photomicrographs of spleen tissue stained with hematoxylin and eosin. Original magnification × 1000; bars = 100 μm. Mice were inoculated
with 5 × 106 parasitized RBCs or saline and treated with BM-MSCs. Spleens were excised 5 days after infection. Normal spleen architecture with white pulp
(double black arrows). Uninfected mice treated with BM-MSCs also displayed normal spleen architecture (double black arrows). In P. berghei-infected mice,
spleen damage was observed with activation of lymphocytes in white pulp, increased deposition of malaria pigment in red pulp (single white arrows), and
increased number of lymphoblasts and lymphocytes in white pulp (red double arrows). b A semiquantitative, severity-based score was used to measure
malaria pigment deposition, inflammation, fibrosis, and histoarchitectural damage in spleens of mice infected with P. berghei or mock-infected with
saline and, 24 hours after infection, treated with BM-MSCs. Values are expressed as median (interquartile range) of six animals in each group. *Significantly
different from uninfected group (p <0.05). +Significantly different from P. berghei-infected group (p <0.05). c Representative dot-plots demonstrating
CD11b+ fluorescence in splenocytes. BM-MSC bone marrow-derived mesenchymal stromal cell, FSC forward scatter, Sal saline
Fig. 4 a Photomicrographs of liver tissue stained with hematoxylin and eosin. Original magnification × 1000; bars = 100 μm. Mice were inoculated with
5 × 106 parasitized RBCs or saline and treated with BM-MSCs. Livers were excised 5 days after infection. Note the intact hepatocytes (single black arrows)
involving the centrolobular vein. Administration of BM-MSCs did not alter the liver architecture (double black arrows) or centrolobular vein in control mice.
P. berghei-infected, saline-treated mice exhibited hepatocyte derangement (double white arrowhead), increased deposition of malaria pigment, and an
increased number of Kupffer cells (single white arrows). BM-MSC therapy increased the number of regenerated hepatocytes and Kupffer cells (double white
arrows). b A semiquantitative, severity-based score was used to measure malaria pigment deposition, inflammation, fibrosis, and histoarchitectural damage
in livers of mice infected with P. berghei or mock-infected with saline and, 24 hours after infection, treated with BM-MSCs. Values are expressed as median
(interquartile range) of six animals in each group. *Significantly different from uninfected group (p <0.05). +Significantly different from P. berghei-infected
group (p <0.05). BM-MSC bone marrow-derived mesenchymal stromal cell, Sal saline
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Fig. 5 a Photomicrographs of kidney tissue stained with hematoxylin and eosin. Original magnification × 1000; bars = 100 μm. Mice were inoculated with
5 × 106 parasitized RBCs or saline and treated with BM-MSCs. Uninfected mice treated or not with BM-MSCs also showed normal kidney architecture (black
arrows). In P. berghei-infected mice treated with saline, mesangial proliferation occurred in the glomeruli (*) with hydropic degeneration of kidney tubular
epithelium (#) and increased deposition of malaria pigment (arrowhead). In P. berghei-infected mice treated with BM-MSCs, normal mesangial cell
architecture (*) and tubular cells (#), and sparse deposition of malaria pigment (arrowhead) were observed. b A semiquantitative, severity-based score
was used to measure malaria pigment deposition, inflammation, fibrosis, and histoarchitectural damage in kidneys of mice infected with P. berghei or
mock-infected with saline and, 24 hours after infection, treated with BM-MSCs. Values are expressed as median (interquartile range) of six animals in each
group. *Significantly different from uninfected group (p <0.05). +Significantly different from P. berghei-infected group (p <0.05). #Significantly different from
uninfected untreated group (p <0.05). BM-MSC bone marrow-derived mesenchymal stromal cell, Sal saline
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Fig. 6 Effects of BM-MSC therapy on renal function in P. berghei-infected
animals. Mice were infected with P. berghei or mock-infected with saline
and, 24 hours after infection, treated with BM-MSCs. Five days after
infection, plasma and urine samples were collected for analysis of renal
function. Analysis of a urinary flow, b plasma creatinine, c blood urea
nitrogen (BUN), d creatinine clearance, e BUN/plasma creatinine, f urinary
creatinine, and g urinary protein/creatinine ratio (UPCr) in different
experimental groups is depicted. Values are expressed as mean ± SD of
six animals per group out of two experiments. *Significantly different from
uninfected group (p <0.05). +Significantly different from P. berghei-infected
group (p <0.05). BM-MSC bone marrow-derived mesenchymal stromal
cell, UPC urinary protein/creatinine
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days are considered resistant, and die from pathological
conditions not related to ECM [4]. BM-MSCs were there-
fore administered 24 hours after P. berghei infection, when
the inflammatory process in different organs was already
present and intense. If treatment was started late in the
course of malaria, when the mortality rate is high, this
would have hampered interpretation of results. Mice were
euthanized 5 days post infection because, at this time
point, several pathological conditions were already present
[25] but the mice were still alive; this approach prevented
misinterpretation of results due to the presence of resist-
ant animals.
Histologically, brains from mice with ECM exhibit cor-
tical edema, congested capillaries, increased numbers of
microglial cells, and glial cell swelling [26–28]. In addition,
Nacer et al. [29] proposed recently that intracranial hyper-
tension plays a crucial role in ECM development. The
authors suggest that intracranial hypertension could be pro-
moted by the presence of late-stage infected erythrocytes,
i.e., schizonts, in postcapillary venules. Interestingly, the re-
duction in parasitemia shown in Fig. 1 was mainly due to
reduction of early-stage (i.e., ring) forms, but not schizonts,
which may explain why BM-MSC treatment did not im-
prove brain tissue damage despite increasing the survival
rate in P. berghei-infected mice. On the other hand, the
number of astrocytes and oligodendrocytes was further in-
creased, which suggests tissue repair [30]. Glial cells have
been described as undergoing apoptosis during ECM [31];
nevertheless, the outcome of ECM does not depend on the
attenuation of glial cell dysfunction [32, 33], suggesting that
this process is not involved in ECM development. Further-
more, glial cells increase neutrophil survival and phagocyt-
osis, which could provide protection against brain infection
[34]. Since cell-based therapy decreases parasite load in
noncerebral malaria models [12, 13], we hypothesized that
BM-MSC administration would stimulate phagocytosis and
promote parasite clearance, which has been extensively de-
scribed in the literature as occurring in the spleen [35, 36].
The spleen is well characterized as a hematopoietic site
during experimental malaria [37]; the increased numbers of
constitutive hematopoietic stem progenitor cells observed
in the spleen during P. berghei infection impair parasitemia
exacerbation and increase mouse survival [23]. This fact
corroborates the hypothesis that treatment with BM-MSCs
promotes parasite clearance and increases survival of in-
fected mice. In the present study, we observed a reduction
in the levels of malaria pigment in the spleen after BM-
MSC therapy, providing further evidence for the aforemen-
tioned improvement in parasite clearance.
In our experiment, C57Bl/6 mice infected with P. berghei
developed not only ECM but also kidney injury, which was
characterized by reduced urinary flow and creatinine
clearance [38]. This renal function impairment has been
Fig. 7 a Photomicrographs of lung parenchyma stained with hematoxylin and eosin. Original magnification × 1000; bars = 100 μm. In uninfected
mice treated or not with BM-MSCs, normal architecture was observed with intact alveolar–capillary barrier (black arrows and white arrows, respectively).
P. berghei infection induced lung damage, associated with structural disarrangement, thickening of the alveolar–capillary barrier by mononuclear cells
(double black arrows) and malaria pigment deposition (red arrowhead), and increased number of fibroblasts (double black arrows). Treatment with
BM-MSCs reduced thickening of the alveolar–capillary barrier and decreased the number of myofibroblasts within interstitial tissue (double black arrow)
and collagen deposition (double black arrows). b A semiquantitative, severity-based score was used to measure malaria pigment deposition, inflammation,
fibrosis, and histoarchitectural damage in lungs of mice infected with P. berghei or mock-infected with saline and, 24 hours after infection, treated with
BM-MSCs. Values are expressed as the median (interquartile range) of six animals in each group. *Significantly different from uninfected group (p <0.05).
+Significantly different from P. berghei-infected group (p <0.05). BM-MSC bone marrow-derived mesenchymal stromal cell, Sal saline
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Fig. 8 Fraction area of mononuclear cells (a) and neutrophils (b).
Static lung elastance (Est,L) (c). Values are the mean ± SD of six
animals in each group. *Significantly different from uninfected group
(p <0.05). +Significantly different from P. berghei-infected group (p
<0.05). BM-MSC bone marrow-derived mesenchymal stromal cell
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even though tissue parasitemia and inflammatory infiltra-
tion were reduced, BM-MSCs did not improve renal func-
tion. This dissociation between reduction in kidney damage
and absence of improvement in renal function may be at-
tributable to the duration of the analysis period, since, in
previous studies, mice that survived ECM continued to ex-
hibit evidence of kidney injury 21 days after clearance of
parasitemia [38].
Some studies have reported that BM-MSCs attenuate
lung inflammation and fibrosis as well as improve pul-
monary function in noninfectious models [40–42]. A
previous study concerning BM-MSC treatment of infec-
tious diseases suggests that lung injury attenuation was
associated with disease recovery [43]. Even though cell-
based therapies have already been used in malaria infec-
tion, no study had thus far investigated the effects of
BM-MSCs on ECM-associated lung damage. BM-MSCs
reduced lung tissue parasitemia as well as neutrophil in-
filtration despite an increase in mononuclear cell counts.
Additionally, BM-MSC treatment reduced lung tissue
damage and fibrosis, thus improving pulmonary func-
tion, which may suggest an association between attenu-
ation of general lung dysfunction attenuation and the
outcome of ECM. In this context, it is known that any
therapy which regulates the lung injury-induced inflam-
matory cascade may also reduce distal organ dysfunction
[44]. The reduction of malaria pigment deposition in
lung tissue could also result in decreased neutrophil ac-
cumulation, thus improving lung morphofunction. How-
ever, attenuation of lung injury after BM-MSC therapy is
not exclusively associated with diminished parasitemia,
since malaria-induced lung injury is not necessarily a
direct consequence of parasitemia [45]. We thus specu-
late that BM-MSCs may improve lung morphofunction
for several reasons: (1) intravenously administered BM-
MSCs accumulate mainly in lung tissue [46]—more
beneficial effects would thus occur in the lung than in
other organs; (2) the decrease in tissue parasitemia
would be associated with increased numbers of lung tis-
sue phagocytic cells [47]; and (3) VEGF, which is the
main factor implicated in malaria-induced lung injury
[45], would be reduced. Corroborating these hypotheses,
we observed that the number of macrophages was in-
deed increased and levels of VEGF were indeed reduced
in lung tissue.
This study has some limitations that should be ad-
dressed. First, ECM was induced by P. berghei inoculation;
Fig. 9 Cytokine production in lung tissue after BM-MSC treatment of P. berghei-infected mice. a Tumor necrosis factor (TNF)-α, b interferon (IFN)-γ,
c chemokine C-X-C motif (CXCL)1/KC, d hepatocyte growth factor (HGF), e transforming growth factor (TGF)-β, and f vascular endothelial growth factor
(VEGF) were evaluated by ELISA. Results are expressed as the mean ± SD of six animals per group. *Significantly different from uninfected group
(p < 0.05). +Significantly different from P. berghei-infected group (p < 0.05). BM-MSC bone marrow-derived mesenchymal stromal cell
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of malaria associated with different degrees of severity or
to human malaria. Second, BM-MSCs were administered
1 day after infection, when the severity of ECM was
reduced compared with day 5 [25]. However, if treatment
had been started late in the course of malaria, the mortal-
ity rate would be high, hampering interpretation of the
results. Additionally, as noted above, mice that survive
longer than 7 days are considered resistant and die of
pathological conditions not related to cerebral malaria [4].
Third, the observation time was relatively short (5 days
post infection), precluding evaluation of the dynamics of
malaria-induced multiple organ dysfunction. However,
several organs were already damaged at day 5—including
the brain, as demonstrated by impaired behavior and cog-
nition. Fourth, no specific antimalarial therapy was given
with BM-MSCs because this study was designed as a proof
of concept rather than an evaluation of optimal therapy.Fifth, BM-MSCs were not tracked within the organs be-
cause markers used for this purpose are usually present for
up to 24 hours and our analysis was carried out on day 5,
when many organs had already been affected by P. berghei
infection.
Conclusions
BM-MSC treatment increased survival and reduced para-
sitemia and malaria pigment deposition in the spleen,
liver, kidney, and lung, but not in the brain. The two main
organs associated with worse prognosis in malaria—the
lung and the kidney—sustained less histological damage
after BM-MSC therapy, with a more pronounced im-
provement in lung function.
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